WT-161 | B2219

WT-161 is a potent, selective, and bioavailable HDAC6 (histone deacetylase-6) inhibitor (IC₅₀ 0.40 nM). It is selective for HDAC6 over HDAC3 (IC₅₀ = 51.61 nM) and induces α-tubulin acetylation, an HDAC6-dependent process, with minimal effect on global lysine acetylation. WT161 inhibits growth of patient-derived multiple myeloma cell lines with IC₅₀ values ranging from 1.5 to 4.7 μM. WT161 enhances the cytotoxicity of bortezomib (Cat. No. 1846) and carfilzomib (Cat. No. 2385) against patient-derived multiple myeloma cells.

WT-161 is a potent, selective, and bioavailable HDAC6 (histone deacetylase-6) inhibitor (IC₅₀ 0.40 nM). It is selective for HDAC6 over HDAC3 (IC₅₀ = 51.61 nM) and induces α-tubulin acetylation, an HDAC6-dependent process, with minimal effect on global lysine acetylation. WT161 inhibits growth of patient-derived multiple myeloma cell lines with IC₅₀ values ranging from 1.5 to 4.7 μM. WT161 enhances the cytotoxicity of bortezomib (Cat. No. 1846) and carfilzomib (Cat. No. 2385) against patient-derived multiple myeloma cells.

B2219 | WT-161 DataSheet

Alternate Name/Synonyms: (E)-8-(2-(4-(Diphenylamino)benzylidene)hydrazinyl)-N-hydroxy-8-oxooctanamide

Appearance: Crystalline solid

Formulation: N/A

CAS Number: 1206731-57-8

Structure Available?: Yes

Peptide sequence: N/A

Salt Form: No

Molecular Formula: C₂₇H₃₀N₄O₃

Molecular Weight: 458.56

Cell-Permeable?: Yes

Purity: ≥98% by HPLC

Solubilities: DMSO

Handling: Protect from air and light

Country of Origin: USA

Tag Line: A potent, selective, and bioavailable HDAC6 (histone deacetylase-6) inhibitor

MDL Number: N/A

PubChem CID: 44601455

SMILES: C1=CC=C(C=C1)N(C2=CC=CC=C2)C3=CC=C(C=C3)C=NNC(=O)CCCCCCC(=O)NO

InChi: InChI=1S/C27H30N4O3/c32-26(15-9-1-2-10-16-27(33)30-34)29-28-21-22-17-19-25(20-18-22)31(23-11-5-3-6-12-23)24-13-7-4-8-14-24/h3-8,11-14,17-21,34H,1-2,9-10,15-16H2,(H,29,32)(H,30,33)/b28-21+

InChi Key: KXWWYFKVBFUVIZ-SGWCAAJKSA-N